ES2191096T3 - Antagonistas de la interleucina-6 humana que es completamente incapaz de unir gp130, y su uso en la preparacion de compuestos farmaceuticos. - Google Patents

Antagonistas de la interleucina-6 humana que es completamente incapaz de unir gp130, y su uso en la preparacion de compuestos farmaceuticos.

Info

Publication number
ES2191096T3
ES2191096T3 ES96912205T ES96912205T ES2191096T3 ES 2191096 T3 ES2191096 T3 ES 2191096T3 ES 96912205 T ES96912205 T ES 96912205T ES 96912205 T ES96912205 T ES 96912205T ES 2191096 T3 ES2191096 T3 ES 2191096T3
Authority
ES
Spain
Prior art keywords
antagonists
human
join
interleucine
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96912205T
Other languages
English (en)
Inventor
Gennaro Ciliberto
Rocco Savino
Giacomo Paonessa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of ES2191096T3 publication Critical patent/ES2191096T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5412IL-6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A ANTAGONISTAS DE LA INTERLEUQUINA 6 HUMANA QUE SON TOTALMENTE INCAPACES DE UNIRSE A LA CADENA DEL RECEPTOR RESPONSABLE DE LA TRANSDUCCION DE LA SEÑAL ASOCIADA CON ESTA CITOQUINA, ESTO ES, CON GP130. LA FIGURA MUESTRA LA AUSENCIA DE INTERACCION ENTRE LOS ANTAGONISTAS DE LA INTERLEUQUINA 6 HUMANA DE ACUERDO CON LA INVENCION Y LA PROTEINA GP130.
ES96912205T 1995-04-28 1996-04-26 Antagonistas de la interleucina-6 humana que es completamente incapaz de unir gp130, y su uso en la preparacion de compuestos farmaceuticos. Expired - Lifetime ES2191096T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT95RM000273A IT1276555B1 (it) 1995-04-28 1995-04-28 Antagonisti di interluchina-6 umana del tutto incapaci di formare un legame con gp 130, e loro uso per la preparazione di composizioni

Publications (1)

Publication Number Publication Date
ES2191096T3 true ES2191096T3 (es) 2003-09-01

Family

ID=11403338

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96912205T Expired - Lifetime ES2191096T3 (es) 1995-04-28 1996-04-26 Antagonistas de la interleucina-6 humana que es completamente incapaz de unir gp130, y su uso en la preparacion de compuestos farmaceuticos.

Country Status (11)

Country Link
US (1) US5972902A (es)
EP (1) EP0822986B1 (es)
JP (2) JP3373856B2 (es)
AT (1) ATE233320T1 (es)
CA (1) CA2218372C (es)
DE (1) DE69626387T2 (es)
DK (1) DK0822986T3 (es)
ES (1) ES2191096T3 (es)
IT (1) IT1276555B1 (es)
PT (1) PT822986E (es)
WO (1) WO1996034104A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2237114A1 (en) * 1995-11-07 1997-05-15 Kaneka Corporation Autoantigens
DE19704979A1 (de) * 1996-02-07 1997-08-14 Max Delbrueck Centrum Retroviraler Vektor für den Gentransfer eines IL6-Antagonisten in humane hämatopoetische Stammzellen
EP2322216A1 (en) 1997-03-21 2011-05-18 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient
IT1291932B1 (it) * 1997-06-20 1999-01-21 Angeletti P Ist Richerche Bio Composizioni farmaceutiche antitumorali capaci anche di ridurre la farmacoresistenza in cellule tumorali, in particolare di carcinoma
CA2400711A1 (en) * 2000-03-06 2001-09-13 Michael John Reed Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase
PT2308888T (pt) * 2001-11-14 2017-05-03 Janssen Biotech Inc Anticorpos anti-il-6, composições, métodos e utilizações
US20050100550A1 (en) * 2003-11-10 2005-05-12 Mohit Trikha Anti-angiogenic uses of IL-6 antagonists
ITRM20050103A1 (it) * 2005-03-10 2006-09-11 Rocco Savino Associazione di antagonisti della interleuchina 6 e farmaci antiproliferativi.
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
CN113698467A (zh) * 2020-05-19 2021-11-26 甘李药业股份有限公司 Il-6变体及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009138A1 (en) * 1992-10-20 1994-04-28 Cetus Oncology Corporation Interleukin-6 receptor antagonists
IT1261787B (it) * 1993-06-23 1996-06-03 Angeletti P Ist Richerche Bio Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.

Also Published As

Publication number Publication date
EP0822986B1 (en) 2003-02-26
US5972902A (en) 1999-10-26
ATE233320T1 (de) 2003-03-15
WO1996034104A1 (en) 1996-10-31
PT822986E (pt) 2003-07-31
JPH10506538A (ja) 1998-06-30
IT1276555B1 (it) 1997-11-03
EP0822986A1 (en) 1998-02-11
DE69626387D1 (de) 2003-04-03
JP2003153691A (ja) 2003-05-27
DK0822986T3 (da) 2003-04-28
ITRM950273A0 (it) 1995-04-28
DE69626387T2 (de) 2003-12-11
JP3373856B2 (ja) 2003-02-04
CA2218372C (en) 2001-07-31
ITRM950273A1 (it) 1996-10-28
CA2218372A1 (en) 1996-10-31

Similar Documents

Publication Publication Date Title
MX9705501A (es) Proteinas accesorias de los receptores de la interleucina 1 humana.
ES2191096T3 (es) Antagonistas de la interleucina-6 humana que es completamente incapaz de unir gp130, y su uso en la preparacion de compuestos farmaceuticos.
IT1288388B1 (it) Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
PT832082E (pt) Derivados de n-heteroaril-piridinossulfonamidas e sua utilizacao como antagonistas de endotelina
ZA948242B (en) Cntf family antagonist
MX9800624A (es) RECEPTORES SOLUBLES DE LINFOTOXINAS- beta Y ANTICUERPOS ANTIRECEPTOR DE LINFOTOXINA Y DE LIGANDO COMO AGENTES TERAPEUTICOS PARA EL TRATAMIENTO DE LA ENFERMEDAD INMUNOLOGICA.
WO2004059285A3 (en) Tumor killing/tumor regression using cxcr4 antagonists
ES2167391T3 (es) Inmunoconjugados ii.
ES2172535T3 (es) Antagonistas de los receptores de la endotelina.
HN1998000155A (es) Medicamentos
ES2190479T3 (es) Moduladores de rxr selectivos a dimeros y metodos para su uso.
NO981477D0 (no) Pyrimidinderivater som 5HT2C-reseptor antagonister
EP0959896A4 (en) COMPOSITIONS BASED ON THE HUMAN THYROTROPIN RECEPTOR AND THEIR USE
AR025883A1 (es) Utilizacion de antagonistas de los receptores de los cannabinoides centrales para la preparacion de medicamentos
ES2196063T3 (es) Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales.
ATE306549T1 (de) C-c ckr-1, ein c-c chemokin rezeptor
ES2171196T3 (es) Uso de antagonistas del receptor cck-b para el tratamiento de trastornos del sueño.
PT954333E (pt) Receptores soluveis de linfotoxina-beta, anticorpos de receptores de anti-linfotoxina e anticorpos de ligandos de anti-linfotoxina como agentes terapeuticos para o tratamento de doencas imunologicas
DE69841322D1 (de) Hepatitis c rezeptorprotein cd81
ES2169763T3 (es) Derivados de pirimidinona.
ES2170056T3 (es) Sistemas de analisis de la actividad de la neurotrofina.
ES2068388T3 (es) Moleculas de receptor de hormona de la glucoproteina.
ES2107431T3 (es) Agentes con accion selectiva sobre los receptores de la adenosina.
ES2166462T3 (es) Antagonistas del receptor de la endotelina.
ES2195002T3 (es) Antagonistas de los receptores de la endotelina.